Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,132.40
(
0.00%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.76
(
-0.88%
)
Bitcoin
73,936.84
(
-0.01%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 99227

Wednesday, 07/21/2010 8:40:46 AM

Wednesday, July 21, 2010 8:40:46 AM

Post# of 257253
Reuters doesn’t get it vis-à-vis GSK’s ‘572:

http://www.reuters.com/article/idCNLDE66J0O020100721

Glaxo will have the option of combining '572 with various other AIDS drugs, including its established product Combivir.

Combining a promising new HIV drug with the archaic Combivir would be throwing good money after bad. I can almost guarantee this is not GSK’s main objective for ‘572.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now